Moderna will begin production of a retooled version of its coronavirus vaccine in the Netherlands, doubling the company’s expected EU production, the company announced Today.
The new contract, signed with subcontractor Lonza, will allow Moderna to manufacture approximately 300 million doses in a year starting at the end of 2021. The Dutch site, in addition to a drug-substance site run by Rovi in Spain, will allow Moderna to make 600 million doses a year in the European Union.
Currently, the US company does not manufacture any drug substances in the EU. Instead, it has outsourced its vaccine material production to Lonza’s site in Switzerland for supply to the European Union, the UK and Canada. But production issues there forced the company to cut estimated deliveries in the UK and Canada earlier this year.
The company supplied 10 million doses to the EU at the end of March, and expects to supply 35 million doses by the end of June.
Moderna’s estimated 600 million doses are based on whether its retractable vaccine requires 50 micrograms of drug substance per dose and is approved by regulators. The company has been testing modified versions of its vaccine, which have been approved in the European Union since early January.